The Acton, Massachusetts-based tubeless insulin pump technology developer posted profits of $12.6 million, or 18¢ per share, on sales of $275.6 million for the three months ended Sept. 30, 2021, for an 8.6% bottom-line gain on sales growth of 17.8%.
Adjusted to exclude one-time items, earnings per share were 18¢, 2¢ behind Wall Street, where analysts were looking for sales of $273.2 million.
Get the full story at our sister site, Drug Delivery Business News.